OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Rational Identification of Novel Antibody‐Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors
Yu Guo, Zheyuan Shen, Wenbin Zhao, et al.
Advanced Science (2024) Vol. 11, Iss. 13
Open Access | Times Cited: 8
Yu Guo, Zheyuan Shen, Wenbin Zhao, et al.
Advanced Science (2024) Vol. 11, Iss. 13
Open Access | Times Cited: 8
Showing 8 citing articles:
Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells
Lucia Kučerová, Adriana Fekiačová, Natália Udvorková, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 287-287
Open Access
Lucia Kučerová, Adriana Fekiačová, Natália Udvorková, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 287-287
Open Access
Trends in the research and development of peptide drug conjugates: artificial intelligence aided design
Donge Zhang, Tong He, Tianyi Shi, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Donge Zhang, Tong He, Tianyi Shi, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing
Éric Larose, Xinying Hua, Silin Yu, et al.
Cancer Drug Resistance (2025)
Open Access
Éric Larose, Xinying Hua, Silin Yu, et al.
Cancer Drug Resistance (2025)
Open Access
Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers
Aurélie Drouin, Laurine Durand, C. Esnault, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010897-e010897
Open Access
Aurélie Drouin, Laurine Durand, C. Esnault, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010897-e010897
Open Access
In-silico Decrypting of the Bystander Effect in Antibody-Drug Conjugates for Breast Cancer Therapy
Juan F. Vega, Víctor L. Cruz, Jorge Duro-Sánchez, et al.
Research Square (Research Square) (2025)
Closed Access
Juan F. Vega, Víctor L. Cruz, Jorge Duro-Sánchez, et al.
Research Square (Research Square) (2025)
Closed Access
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
(2024)
Open Access | Times Cited: 2
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
(2024)
Open Access | Times Cited: 2
An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1124-1124
Open Access | Times Cited: 2
Anca Butucă, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1124-1124
Open Access | Times Cited: 2
Targeted Therapeutic Strategies for Nectin-4 in Breast Cancer: Recent Advances and Future Prospects
Yufei Wang, Guangliang Li, Han-Ying Wang, et al.
The Breast (2024) Vol. 79, pp. 103838-103838
Open Access
Yufei Wang, Guangliang Li, Han-Ying Wang, et al.
The Breast (2024) Vol. 79, pp. 103838-103838
Open Access
